Merck (MRK) Completes Spinoff of Women's Health Company Organon (OGN), Street Starts with Muted Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 5/13/2024
- Squarespace, Inc. (SQSP) To Go Private For $44/shr In Cash With Permira
- It's time to buy the AI dip in chip stocks: Jefferies
- Xponential Fitness (XPOF) removes Anthony Geisler from his duties and suspended him indefinitely as CEO
- Axalta Coating Systems (AXTA) to Acquire The CoverFlexx Group for Up to $295M Cash
- Google stock slips on Apple-ChatGPT rumors; OpenAI to reveal updates
- Intel, Arm, Apple, GameStop rise premarket; Bristol Myers falls
- Midday movers: Novavax, Nvidia, Sweetgreen rise; Moderna, Yelp fall
- After-hours movers: Akamai Technologies, Unity, Macrogenics and more
- Midday movers: Roblox, Airbnb fall; Trade Desk, AppLovin and Bumble rise
- After-hours movers: Robinhood, AppLovin rise; Airbnb, Arm fall, and more
Merck (MRK) Reports New Data on KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) Versus Sunitinib from Pivotal Phase 3 CLEAR/KEYNOTE-581 Trial
June 7, 2021 6:48 AM EDTMerck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai Inc. today announced new investigational data from the pivotal Phase 3 CLEAR (Study 307)/KEYNOTE-581 trial, which evaluated the combinations of KEYTRUDA, Mercks anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, and LENVIMA plus everolimus versus sunitinib for the first-line treatment of patients with advanced renal cell carcinoma (RCC). Results from a new analysis evaluating health-related quality of life (HRQoL) based on patient-reported outcomes are being presented during an oral abstract session at the 2021... More
